KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Johnson & Johnson (JNJ) over the last 17 years, with Q3 2025 value amounting to $18.2 billion.

  • Johnson & Johnson's Cash & Equivalents fell 875.38% to $18.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 billion, marking a year-over-year decrease of 875.38%. This contributed to the annual value of $24.1 billion for FY2024, which is 1027.49% up from last year.
  • Per Johnson & Johnson's latest filing, its Cash & Equivalents stood at $18.2 billion for Q3 2025, which was down 875.38% from $18.6 billion recorded in Q2 2025.
  • Johnson & Johnson's Cash & Equivalents' 5-year high stood at $38.5 billion during Q1 2025, with a 5-year trough of $10.5 billion in Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $18.4 billion (2025), whereas its average is $18.5 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 3549.76% in 2022, then skyrocketed by 9287.08% in 2023.
  • Johnson & Johnson's Cash & Equivalents (Quarter) stood at $17.6 billion in 2021, then crashed by 35.5% to $11.4 billion in 2022, then surged by 92.51% to $21.9 billion in 2023, then rose by 10.27% to $24.1 billion in 2024, then decreased by 24.37% to $18.2 billion in 2025.
  • Its Cash & Equivalents was $18.2 billion in Q3 2025, compared to $18.6 billion in Q2 2025 and $38.5 billion in Q1 2025.